Geftinat 250mg Gefitinib Tablets

3200/Bottle INR

Get a Price/Quote

Product Details:

Drug Type Specific Drug
Physical Form Tablets
Dosage 250 mg
Suitable For Adults, Women
Supply Ability : 10000000 Piece Per Week
Click to view more
Share Your Product:

Ask A Question Send Inquiry

Price And Quantity

Minimum Order Quantity 10000000 Piece
Price 3200/Bottle INR

Product Specifications

Suitable For Adults, Women
Physical Form Tablets
Drug Type Specific Drug
Dosage 250 mg

Trade Information

Payment Terms Cash in Advance (CID), Cash Advance (CA)
Supply Ability 10000000 Piece Per Week
Delivery Time 1 Week
Main Export Market(s) Africa, Middle East, Western Europe, Eastern Europe, South America, North America, Central America, Australia, Asia

Product Description

Geftinat - IRESSA® (Geftinat tablets) contain 250 mg of Geftinat and are available as brown film-coated tablets for daily oral administration. IRESSA is indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies. The effectiveness of IRESSA is based on objective response rates (see CLINICAL PHARMACOLOGY — Clinical Studies section). There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival. Results from two large, controlled, randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy. Therefore, IRESSA is not indicated for use in this setting. Active ingredients: Gefitinib